Showing results (91-100 of 178) with videos related to

Sort By:
Pageof 18
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Investigational New Drugs|March 20, 2020
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRJames M Cleary, Emiliano Calvo, Victor Moreno, et al.
The Oncologist|January 20, 2025
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancerEmiliano Calvo, Bernard Doger, Joan Carles, et al.
Clinical Epigenetics|July 9, 2026
Tumor-type specific methylation patterns of MTAP in human samples and cell linesLuis Álvarez-Carrión, Dalma Müller, Manuel Pedregal, et al.
ACS Omega|December 1, 2025
Understanding the Chemical Characteristics of Payloads and the Expression of Tumor-Associated Antigens of ADCs in Clinical DevelopmentCristina Nieto-Jiménez, Lucía Paniagua-Herranz, Carlo Bosi, et al.
Investigational New Drugs|March 11, 2021
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I studyMaría Eugenia Olmedo, Martin Forster, Victor Moreno, et al.
Frontiers in Oncology|March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapiesChristin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast CancerSara M Tolaney, Young-Hyuck Im, Emiliano Calvo, et al.
British Journal of Cancer|May 26, 2023
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumorsAnthony B El-Khoueiry, James Clarke, Tobias Neff, et al.
Cancer Medicine|July 6, 2024
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumorsAgostina Stradella, Melissa Johnson, Sanjay Goel, et al.
Pageof 18